Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1423-1432, 2007. First published June 15, 2007; 10.1373/clinchem.2007.088104
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 088104.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.088104v1
53/8/1423    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (26)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaw, J. L.V.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaw, J. L.V.
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1423-1432.)
© 2007 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Distribution of 15 Human Kallikreins in Tissues and Biological Fluids

Julie L.V. Shaw1,2 and Eleftherios P. Diamandis1,2,a

1 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

aAddress correspondence to this author at: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St., Box 32, Rm. L6-206, Toronto, Ontario, Canada M5G 1X5. Fax 416-619-5521; e-mail ediamandis{at}mtsinai.on.ca.

Background: Kallikreins (KLKs) are a group of 15 secreted serine proteases. Some KLKs are established or candidate cancer biomarkers, but for most the physiological function is unknown. We characterized the protein and mRNA abundance patterns of all 15 KLKs in multiple panels of human tissues and biological fluids.

Methods: We used sensitive and specific sandwich-type ELISAs for each KLK. Reverse transcription PCR was used for transcript amplification. Multiple panels of human tissue extracts (adult and fetal) were tested, along with various biological fluids.

Results: Quantitative protein expression data on 7 sets of adult and 3 sets of fetal tissues were collected for all 15 KLKs. KLKs were also quantified in the following biological fluids: seminal plasma, breast milk, follicular fluid, breast cyst fluid, breast cancer cytosol, amniotic fluid, ovarian cancer ascites, cerebrospinal fluid, cervicovaginal fluid, and urine. The data were used to generate heat maps of KLK concentrations in tissues and fluids and categorize KLK abundance as highly restricted (KLK2 and KLK3 in prostate), restricted (KLK5 in skin, salivary gland, breast, and esophagus; KLK6 in brain and central nervous system; KLK7 in esophagus, heart, liver, and skin; KLK8 in breast, esophagus, skin, and tonsil; KLK13 in esophagus and tonsil), or wide (KLKs 1, 4, 9, 10, 11, 12, 14, and 15).

Conclusions: Quantitative KLK concentrations in tissues and fluids aid in the elucidation of KLK function, and coexpression patterns provide clues for KLK participation in proteolytic cascades.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
N. Emami and E. P. Diamandis
Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers
Clin. Chem., October 1, 2008; 54(10): 1600 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Prassas, M. Paliouras, A. Datti, and E. P. Diamandis
High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies
Clin. Cancer Res., September 15, 2008; 14(18): 5778 - 5784.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Emami, D. Deperthes, J. Malm, and E. P. Diamandis
Major Role of Human KLK14 in Seminal Clot Liquefaction
J. Biol. Chem., July 11, 2008; 283(28): 19561 - 19569.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Planque, L. Li, Y. Zheng, A. Soosaipillai, K. Reckamp, D. Chia, E. P. Diamandis, and L. Goodglick
A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma
Clin. Cancer Res., March 1, 2008; 14(5): 1355 - 1362.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Emami and E. P. Diamandis
Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade: POSSIBLE FUNCTION IN SEMINAL PLASMA AND SKIN
J. Biol. Chem., February 8, 2008; 283(6): 3031 - 3041.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.